Global Sitagliptin Market 2020-2024 Flourishing with Merck, Yonta, Haikang Pharma, Baoling Pharma, Phebra

The growing demand for Sitagliptin has provided a major boost to the Global Sitagliptin Market as more people are shifting their preferences to this growing sector. The market is expected to keep rising at a high CAGR and reach values of high millions by the end of the forecast period of 2020 up to 2024.

Overview of Global Sitagliptin Market:

Sitagliptin, sold under the brand name Januvia among others, is a medication used to treat diabetes mellitus type 2. In the United Kingdom Sitagliptin is listed as less preferred than metformin or a sulfonylurea. Sitagliptin is also available within a single pill as metformin/sitagliptin.

The report contains a complete product overview and its scope in the market to define the key terms and provide the clients a holistic idea of the market and its tendency. It comprehensively evaluates the global Sitagliptin market with different perspectives for the purpose of providing a detailed, informative, and accurate analysis of regional growth, competition, market segmentation, and other important aspects.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/268028 .

Growth in the historic period resulted from economic growth in emerging markets, the rise in awareness of the benefits and developed nations towards Sitagliptin costs and an increase in the number of medication used to treat diabetes.

Product Type Segmentation:
The Sitagliptin market have different product type such as Injection and Tablets. Sitagliptin market product type gives medication used to treat diabetes. Sitagliptin is taken by mouth in tablets form.

Industry Segmentation:

Increasing instances across various sectors such as Diabetes and Epilepsy are raising the need of diabetes institutes, thereby raising the demand for Sitagliptin market. This help in the profitable growth of the Global Sitagliptin market in upcoming year.

Segmentation by Regions:

The Sitagliptin market in North America has created medication used to treat diabetes to help diabetes and epilepsy patient in the world. It was followed by Western Europe, China, Japan, Southeast Asia, India and Central & South America regions. Asia Pacific is expected to record higher growth rate in Sitagliptin Market during the forecast year.

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on "Global Sitagliptin Market Report 2020" @ https://www.businessindustryreports.com/buy-now/268028/single .

Top Leading Key Manufacturers are: Merck, De Xiang Pharmaceutical &Chemicals, Yonta, Haikang Pharma, Baoling Pharma, Phebra. New product launches and continuous technological innovations are the key strategies adopted by the major players.

Top Industry News:

Merck's KEYTRUDA (pembrolizumab) Superior to Standard of Care Chemotherapy in Patients with MSI-H Colorectal Cancer on 28 May, 2020 -- Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from KEYNOTE-177, a Phase 3 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for the first-line treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic colorectal cancer. In this pivotal study, KEYTRUDA monotherapy significantly reduced the risk of disease progression or death by 40% (HR=0.60 [95% CI, 0.45-0.80; p=0.0002]) and showed a median progression-free survival (PFS) of 16.5 months compared with 8.2 months for patients treated with chemotherapy (investigator's choice of mFOLFOX6 or FOLFIRI, with or without bevacizumab or cetuximab), a current standard of care in this patient population. As previously announced, the study will continue without changes to evaluate overall survival (OS), the other dual primary endpoint. These results were selected for presentation on Sunday, May 31, 2020 in the plenary session of the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #LBA4).

"For many years, the standard of care for the first-line treatment of patients with MSI-H colorectal cancer has been the combination of mFOLFOX6 plus bevacizumab. This is the first time a single-agent, anti-PD-1 therapy demonstrated a superior, statistically significant and clinically meaningful improvement in progression-free survival compared to chemotherapy for these patients," said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. "There is an unmet need for new treatment options in the first-line setting that may provide sustained, long-term improvements in outcomes for patients with MSI-H colorectal cancer. We are grateful to have the opportunity to present these practice-changing findings at the plenary session of this year's ASCO."

"KEYTRUDA monotherapy significantly reduced the risk of disease progression or death by 40% versus standard of care chemotherapy, with fewer treatment-related adverse events observed, in patients with MSI-H metastatic colorectal cancer. KEYTRUDA also demonstrated a long-term, durable response that lasted over two years for those who responded to treatment," said Thierry Andre, MD, professor of medical oncology, Sorbonne University, and Head of the Medical Oncology Department in St. Antoine Hospital, Assistance Publique Hopitaux de Paris. "Data from KEYNOTE-177 show that KEYTRUDA monotherapy has the potential to become the new standard of care for first-line treatment of patients with MSI-H metastatic colorectal cancer."

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/268028 .

Major Points in Table of Contents:

1 Sitagliptin Product Definition
2 Global Sitagliptin Market Manufacturer Share and Market Overview
2.1 Global Manufacturer Sitagliptin Shipments
2.2 Global Manufacturer Sitagliptin Business Revenue
2.3 Global Sitagliptin Market Overview
2.4 COVID-19 Impact on Sitagliptin Industry
3 Manufacturer Sitagliptin Business Introduction
3.1 Merck Sitagliptin Business Introduction
3.1.1 Merck Sitagliptin Shipments, Price, Revenue and Gross profit 2014-2019
3.1.2 Merck Sitagliptin Business Distribution by Region
3.1.3 Merck Interview Record
3.1.4 Merck Sitagliptin Business Profile
3.1.5 Merck Sitagliptin Product Specification
3.2 De Xiang Pharmaceutical&Chemicals Sitagliptin Business Introduction
3.2.1 De Xiang Pharmaceutical&Chemicals Sitagliptin Shipments, Price, Revenue and Gross profit 2014-2019
3.2.2 De Xiang Pharmaceutical&Chemicals Sitagliptin Business Distribution by Region
3.2.3 Interview Record
3.2.4 De Xiang Pharmaceutical&Chemicals Sitagliptin Business Overview
3.2.5 De Xiang Pharmaceutical&Chemicals Sitagliptin Product Specification
3.3 Yonta Sitagliptin Business Introduction
3.3.1 Yonta Sitagliptin Shipments, Price, Revenue and Gross profit 2014-2019
3.3.2 Yonta Sitagliptin Business Distribution by Region
3.3.3 Interview Record
3.3.4 Yonta Sitagliptin Business Overview
3.3.5 Yonta Sitagliptin Product Specification
3.4 Haikang Pharma Sitagliptin Business Introduction
3.5 Baoling Pharma Sitagliptin Business Introduction
3.6 Phebra Sitagliptin Business Introduction
................... Request free sample to get a complete Table of Content

About us

BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined - we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune - India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.